Search

everythinglearnresearchcommunity

for

Search:↓

Prostate cancer was a major health issue in 2009, especially for Black men, and targeting the 5alpha-reductase enzyme could help in its prevention and treatment.

5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.

Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.

Selenium and vitamin E supplements have mixed effects on prostate cancer risk and may not be beneficial for everyone.

Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.

A protein called CBP is found in prostate cancer and can increase the effectiveness of certain prostate cancer treatments.

Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.

Prostate cells have proteins that bind to specific hormones, which can increase protein production when activated by these hormones.

Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.

The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.

Steroid sex hormones activate matriptase in prostate cancer cells but not in breast cancer cells.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.

Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Men who experienced baldness at age 20 may have double the risk of getting prostate cancer.

Large prostate links to more hair loss, but age of onset doesn't affect it.

Estradiol and castration reduced prostate cancer development in rats when applied at early stages, but were ineffective after cancer was established.

The study found no link between baldness patterns and androgen levels in men with benign prostate enlargement or prostate cancer.

Men who start losing hair at age 30 may have a lower risk of prostate cancer.

Baldness at age 40 is not linked to a higher risk of aggressive prostate cancer.

Suppressing certain hormones might help prevent prostate cancer.

Early-onset baldness is linked to a higher risk of aggressive prostate cancer in African-American men, especially before age 60.

Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.

The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.

Men with male pattern baldness have a higher risk of dying from prostate cancer.

Early balding at 40 increases prostate cancer risk.

Prostate-specific antigen may be a new marker for excess male hormones in women with polycystic ovary syndrome.

5 alpha-reductase inhibitors like finasteride may lower prostate cancer risk and improve cancer screening.

The activity of a specific rat enzyme in the prostate and epididymis is highly dependent on the acidity level.